C12N 15/11 - DNA or RNA fragmentsModified forms thereof
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
Provided herein are engineered AAV capsids with improved biodistribution and transduction efficiency in microglia, e.g., in the brain, compositions comprising the capsids, and methods of using the same.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C07K 14/015 - Parvoviridae, e.g. feline panleukopenia virus, human parvovirus
C07D 209/02 - Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
C07D 495/02 - Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
4.
METHODS OF EARLY IDENTIFICATION AND EARLY INTERVENTION FOR HIGH-RISK NEONATES WHO OTHERWISE WILL DEVELOP AUTISTIC SOCIAL IMPAIRMENTS LATER IN LIFE
Disclosed herein are methods and kits for assessing a. risk of subject developing autism spectrum disorder (ASD). The methods can include determining a level of Limosilactobacillusreuteri in a sample from the subject, or receiving results of a test indicating a level of L. reuteri in a. sample from the subject, and determining the risk of developing ASD in the subject, based at least partly on the level of L. reuteri in a sample from the subject.
C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
A method for determining a hemodynamic parameter of a patient using a blood flow system is provided. The method includes using the blood flow system having an extracorporeal pump to circulate a patient's blood through a hemodynamic circuit with a flow characterized by a primary flow rate. The hemodynamic circuit includes an extracorporeal circuit and the patient's vasculature. The method further includes measuring physiological patient data that characterizes pressure parameters and flow data at at least two time points while perturbing the flow of the patient's blood through the hemodynamic circuit according to a flow modulation function. The method also includes using a processor to determine a hemodynamic parameter of the patient based on a relationship between the pressure parameters and flow data and generating a report based on the hemodynamic parameter.
A61B 5/021 - Measuring pressure in heart or blood vessels
A61M 1/36 - Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation
A61M 1/00 - Suction or pumping devices for medical purposesDevices for carrying-off, for treatment of, or for carrying-over, body-liquidsDrainage systems
6.
COMPOSITIONS AND METHODS FOR REDUCING CELL THERAPY IMMUNOGENICITY
This application provides, in part, methods and compositions for decreasing the immunogenicity of cell therapies (e.g., CAR-T cell therapies) using inhibitors of transporter associated with antigen processing (TAPi) and oligonucleotides that decrease the expression of an immunogenic proteins (e.g., MHC Class I and Class II).
A61P 35/02 - Antineoplastic agents specific for leukemia
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
7.
MODULATION OF BACE1 AS A THERAPY FOR SPINOCEREBELLAR ATAXIA
Described herein are methods and compositions for treating neurodegenerative diseases including Spinocerebellar Ataxia comprising administering a BACE1 inhibitor.
A61K 31/549 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
A61K 31/366 - Lactones having six-membered rings, e.g. delta-lactones
A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
A61K 31/541 - Non-condensed thiazines containing further heterocyclic rings
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
Compositions and methods for assessing relative macromolecule abundance (for example, RNA expression levels) in a spatially-defined manner across a tissue sample (for example, from brain, lung, liver, kidney, pancreas, and/or heart) are disclosed, specifically providing deep transcriptomic coverage at high-resolution (for example, at approximate 10 μm (single cell) resolution) across multiple locations assessed across the tissue sample
The present invention provides compositions and methods for detecting miRNA in a biological sample. The compositions and methods employ a polynucleotide substrate and that is cleaved by a CRISPR/CAS system upon sensing of a miRNA in a sample, thus releasing particles attached to the polynucleotide substrate. These particles (e.g., gold nanoparticles) can then be detected, e.g., by dark field microscopy, to identify the presence of miRNA in the sample.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
Described herein are methods of assessing the risk of dementia in a subject using an odor-based test, or "smell test". These methods can be self-administered by the subject under the instruction of a computing device via a user interface. Methods of administering a smell test as described herein can optionally be combined with measuring and quantifying the level of at least one biomarker for dementia (e.g., CXCL10, CCL2, IL-6) in a biological sample collected from the subject. Also provided are methods to treat dementia (e.g., dementia associated with Alzheimer's disease, dementia associated with a subset of Alzheimer's disease patients with TDP-43 pathology).
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
Described herein are methods for treating a carcinoma in a subject, the method comprising administering to the subject a therapeutically effective amount of (5z)-7-oxozeaenol (Oxo) or an analog thereof, optionally in combination with chemotherapy.
A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/555 - Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
This disclosure relates to methods of using shear-thinning compositions in the treatment of a vascular disorders, cancers, infections, abscesses, and fistulas. The disclosure also relates to shear-thinning compositions comprising silicate nanoparticles, gelatin or a derivative thereof, and a contrast agent. In some examples, the shear-thinning compositions comprise about 1.5% to about 10% by weight of silicate nanoparticles and about 0.5% to about 6.75% by weight of gelatin or a derivative thereof.
A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid
13.
COMPOSITIONS AND METHODS THAT PROMOTE HYPOXIA OR THE HYPOXIA RESPONSE FOR TREATMENT AND PREVENTION OF MITOCHONDRIAL DYSFUNCTION AND OXIDATIVE STRESS DISORDERS
A system includes an enclosed tent or chamber or a breathing apparatus, a hypoxia induction system and a device for measuring arterial oxygen saturation in a subject breathing air within the enclosed tent or chamber or from the breathing apparatus. The hypoxia induction system delivers oxygen-depleted air having between 5 to 20% O2 to the enclosed tent or chamber or breathing apparatus. The system adjusts the oxygen content of the oxygen-depleted air being delivered to the enclosed tent or chamber or the breathing apparatus based upon the arterial oxygen saturation measured by the device such that oxygen saturation in the subject is maintained within a range of 50% to 90%.
A61K 31/472 - Non-condensed isoquinolines, e.g. papaverine
A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A system and method for fast fluorescence lifetime imaging are presented. The system includes a light source that delivers periodically modulated light to tissue that has received a fluorescent compound. The system also includes a detector system that is configured to receive light fluoresced by the tissue and produce fluorescence lifetime (FLT) data. The FLT data includes continuous wave data and time gated data measured with a given frequency and phase. The system also includes a processor that is configured to analyze the FLT data to estimate a fluorescence lifetime at a plurality of locations across the tissue and to determine a presence or absence of cancer in the tissue based on the estimate of the fluorescence lifetime at the plurality of locations across the tissue.
G16H 15/00 - ICT specially adapted for medical reports, e.g. generation or transmission thereof
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
A61B 1/06 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor with illuminating arrangements
15.
SYSTEM AND METHOD OF TREATING VAGINAL INFECTIONS AND INFLAMMATION
Systems and methods are provided for treating vaginal infections. The system includes a body sized to be inserted to the vagina of a subject, and the body includes a wall with fenestrations to allow air flow to circulate from inside the body to outside the body. The system also includes a light emitter positioned within the body to emit light outward along a length of the body.
The present disclosure relates to direct immobilization of antibodies by physisorption onto plain and nanostructured metal-containing films. An exemplary method for preparing a sensor includes contacting an antibody with a surface of a film comprising an ionic compound and a metal selected from gold, silver, platinum, copper, and any combination thereof, and then contacting a blocking agent with the surface of the film to form the sensor.
Artificial intelligence enabled disease profiling is described. An electrocardiogram analysis module is configured to derive disease vectors for a plurality of diseases using electrocardiogram training data from both disease-negative and disease-positive individuals. A standardized input is generated, via a data preprocessor of the electrocardiogram analysis module, from an electrocardiogram recorded from an individual. The standardized input is encoded, by a deep learning autoencoder of the electrocardiogram analysis module, into an embedding, the embedding being a lower-dimensional latent space representation of features extracted from the standardized input. At least one disease risk score for the individual is generated, by a statistical modeling algorithm of the electrocardiogram analysis module, for the plurality of diseases based on the embedding and the disease vectors.
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
18.
LIPID NANOPARTICLES FOR THE TREATMENT OF VASCULAR DISEASES
Described herein are lipid nanoparticle (LNP) formulations with demonstrated tropism towards smooth muscle cells. Also described herein are LNPs conjugated with peptides that can target tissue or cell surface receptors. The formulations of the disclosure include amounts of DOTAP, an ionizable lipid, amounts of a neutral lipid; amounts of cholesterol; and amounts of one or more PEG-lipids with preferential tropism towards vascular smooth muscle cells (vSMCs). Also described herein are peptides that target receptors highly expressed on the surface of vSMCs (IL-6R, CD63 and GAL-3) or that target proteins in the extracellular matrix adjacent to vSMCs (Col-IV) increasing the uptake into these cells.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
19.
METHODS FOR UTILIZING COMMENSAL POLYOMAVIRUS FOR CANCER THERAPY
Provided herein are methods for treating a cancer, e.g., a solid tumor and/or a blood cancer, using a polyomavirus in a subject in need thereof. The methods further include treating the cancer with an additional cancer therapy, e.g., surgery, radiation, chemotherapy, and/or immunotherapy. Additionally, provided herein are methods of using polyomavirus for immune system activation for the prevention of cancer.
Methods and systems are provided for obtaining microcored tissue samples from a living subject that minimize scarring while providing samples suitable for various tissue analyses. A hollow microcoring needle is provided having a diameter less than about 1 mm, a tip configured to pierce skin or other tissue, and a plurality of holes or openings along the needle walls to facilitate exposure of the tissue within the needle to various substances. A needle containing an extracted tissue sample can be placed in a fixating solution such as a 10% buffered formalin solution, then processed to infiltrate the tissue with paraffin. The fixated tissue is removed from the needle by pushing a wire through the needle core to eject it. The tissue can optionally be treated with various substances while encased within the needle prior to fixation and further processing.
Systems and methods of universal input scaling perform and/or comprise receiving at least one input signal from at least one input source; ranking a signal parameter of the at least one input signal and generating a profile of the signal parameter; detecting a target signal in a full spectrum of the at least one input signal; forwarding the target signal to a signal processing unit; and processing the target signal based on the profile.
G10L 25/00 - Speech or voice analysis techniques not restricted to a single one of groups
H04R 1/40 - Arrangements for obtaining desired frequency or directional characteristics for obtaining desired directional characteristic only by combining a number of identical transducers
22.
PANELS AND METHODS FOR TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA
The present disclosure provides a molecular classifier and a targeted sequencing assay for use in characterization and treatment of diffuse large B-cell lymphoma.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
23.
PANELS AND METHODS FOR TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA
The present disclosure provides a molecular classifier and a targeted sequencing assay for use in characterization and treatment of diffuse large B-cell lymphoma.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
G16B 20/20 - Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
Described herein are lipid nanoparticle (LNP) formulations with demonstrated tropism towards smooth muscle cells. Also described herein are LNPs conjugated with peptides that can target tissue or cell surface receptors. The formulations of the disclosure include amounts of DOTAP, an ionizable lipid, amounts of a neutral lipid; amounts of cholesterol; and amounts of one or more PEG-lipids with preferential tropism towards vascular smooth muscle cells (vSMCs). Also described herein are peptides that target receptors highly expressed on the surface of vSMCs (1L-6R, CD63 and GAL-3) or that target proteins in the extracellular matrix adjacent to vSMCs (Col-IV) increasing the uptake into these cells.
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 47/28 - Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61K 9/1272 - Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
25.
ENPP1 GENE THERAPY FOR THE TREATMENT OF VASCULAR DISEASE
Provided herein are compositions and methods for gene therapy for disorders of arterial calcification as well as Generalized Arterial Calcification of Infancy (GACI). The methods include a gene addition strategy to deliver a DNA construct to target tissues (such as liver and smooth muscle cells) to express soluble recombinant ENPP1 (srENPP1) or transmembrane full-length recombinant ENPP1 (rENPP1).
The invention features a microfluidic device including an inlet in fluid communication with a channel including an array including one or more rows of posts, wherein each row of posts includes one or more capture areas and one or more passing areas, wherein the one or more capture areas includes the posts and the passing area does not include any posts.
B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
G01N 33/537 - ImmunoassayBiospecific binding assayMaterials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
G01N 15/14 - Optical investigation techniques, e.g. flow cytometry
CENTER FOR DRUG DISCOVERY, RTI INTERNATIONAL (USA)
PRESIDENT AND FELLOWS OF HARVARD COLLEGE (USA)
Inventor
Collins, James Joseph
Krishnan, Aarti
Valeri, Jacqueline Alexus
Wong, Felix J.
Jin, Wengong
Anahtar, Melis Nuray
Luttens, Andreas
Blough, Bruce
Jin, Chunyang
Abstract
Pharmaceutical compositions are disclosed. The pharmaceutical compositions include an antimicrobial compound. The compositions can also include a pharmaceutically acceptable carrier. Discovery methods for discovery of antimicrobial compounds are also disclosed. The discovery methods employ a trained machine learning model to identify substructures of chemical compounds that are predicted to exhibit antimicrobial activity. Antimicrobial activity of known compounds can be discovered and antimicrobial compounds with identified substructures can be generated and/or synthesized.
Provided herein are compositions and methods for gene therapy for disorders of arterial calcification as well as Generalized Arterial Calcification of Infancy (GACI). The methods include a gene addition strategy to deliver a DNA construct to target tissues (such as liver and smooth muscle cells) to express soluble recombinant ENPP1 (srENPP1) or transmembrane full-length recombinant ENPP1 (rENPP1).
C12N 9/16 - Hydrolases (3.) acting on ester bonds (3.1)
A61K 31/711 - Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
Disclosed is a method for regenerating and/or repairing lung tissue in a subject. The method comprises administering to a subject in need of lung tissue regeneration and/or repair a composition including (i) a carrier comprising a scaffold-forming material, (ii) cellular material selected from the group consisting of endothelial cells, epithelial cells, mesenchymal stem cells, and mixtures thereof, and (iii) pneumocytes. In one embodiment of the method, the administering is intravenously or intratracheally. The administering can be via airways to the lung. The scaffold-forming material can comprise (i) a first biopolymer having a first reactive group; (ii) a second biopolymer having a second reactive group, wherein the first reactive group and the second reactive group react via click chemistry to crosslink the first biopolymer and the second biopolymer to form a hydrogel; (iii) a porogen; and a (iv) porogen-degrading agent.
The present disclosure relates to drug-conjugate molecules that release a biologically active payload upon exposure to ionizing radiation. Localized x-ray irradiation releases the payload under normoxic and/or hypoxic conditions that are traditionally associated with radiotherapy resistance.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
Provided herein are compositions, kits, and methods of making biodegradable compositions for localized drug delivery. The drug delivery compositions include one or more therapeutic agents that are dispersed within polymerized macromers of the drug delivery composition, loaded within biopolymeric nanoparticles within the drug delivery composition, or both. The release profiles of the one or more therapeutic agents are tunable based on the one or more therapeutic agents for a desired application.
A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
A61K 31/7036 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
A glucose control system employs adaptation of a glucose target (set-point) control variable in controlling delivery of insulin to a subject to maintain euglycemia. The glucose target adapts based on trends in actual glucose level (e.g., measured blood glucose in the subject), and/or computed doses of a counter-regulatory agent such as glucagon. An adaptation region with upper and lower bounds for the glucose target may be imposed. Generally the disclosed techniques can provide for robust and safe glucose level control. Adaptation may be based on computed doses of a counter-regulatory agent whether or not such agent is actually delivered to the subject, and may be used for example to adjust operation in a bihormonal system during periods in which the counter-regulatory agent is not available for delivery.
Described herein are perfusable 3D tubule-on-chip models comprising at least one tubule consisting of one patent lumen circumscribed by organoid-derived cells, and a multifluidic platform comprising at least one individually addressable chip. The models may further include an unseeded tubule, where the seeded tubule and the unseeded tubule are co-localized on the chip, and wherein the tubule and the unseeded tubule are embedded within a gelatin-fibrin extracellular matrix (ECM). Also, described here are methods of producing the described perfusable 3D tubule-on-chip models, and uses of the same.
Provided herein are methods and immune biomarkers that identify progression and treatment options for hematological malignancies (e.g., smoldering multiple myeloma (SMM), monoclonal gammopathy of undetermined significance (MGUS), or multiple myeloma (MM)). Also provided are materials and methods for the prognosis, staging, and monitoring of SMM, MGUS, or MM based on the presence of the immune biomarkers in a sample (e.g., a blood sample or a bone marrow sample), as well as methods for monitoring the progression of SMM, MGUS, or MM, determining the efficacy of a therapeutic agent, determining a treatment for SMM, MGUS (e.g., before progression to MM), or MM, and/or treating SMM, MGUS, or MM. The methods provided herein provide several advantages over invasive biopsies.
G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
36.
Novel Treatment of Diabetes and Kidney Disease by Inhibition of D2D3 a Proteolytic UPAR
The current invention discloses methods for treating diseases characterized by elevated levels of the urokinase plasminogen activator receptor (uPAR) protein D2D3 wherein the disease is one or more of chronic kidney disease, insulin-dependent diabetes, or diabetic neuropathy. In addition, the invention provides methods for restoring pancreatic β-cell number and function in the pancreas of a subject diagnosed with insulin-dependent diabetes wherein the insulin-dependent diabetes is characterized by the presence of detectable levels of D2D3 Specifically, the methods comprise administration of a therapeutically effective amount of an agent that antagonizes or removes D2D3 from the circulation of the subject wherein the agent comprises an anti-D2D3 antibody or antigen binding fragment thereof that specifically binds to a D2D3 protein. Alternatively, the methods comprise removing the D2D3 protein from the circulation of the subject by an extracorporeal procedure.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
37.
DEVICES, SYSTEMS, AND METHODS FOR CAPTURING TARGETS
The present document relates to microfluidic devices and microfluidic systems for capturing a target of interest. Also described herein are methods of isolating or capturing such targets.
C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
C12Q 1/6804 - Nucleic acid analysis using immunogens
THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (USA)
Inventor
Aragam, Krishna
Huffman, Jennifer
Gaziano, Liam
Abstract
Provided herein are methods and compositions for the diagnosis, prognosis, and treatment of dilated cardiomyopathy (DCM) and heart failure (HF). In particular, provided are methods and compositions for detecting a loss-of-function mutation in the CD36 gene. Provided are methods of determining the likelihood that a subject will respond to a treatment for DCM or HF, based on the identification of a CD36 mutation in a sample from the subject.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
39.
SYSTEMS AND METHODS FOR CONTROLLING E-FIELD INTENSITY FOR A SCALP REGION AND A BRAIN REGION USING A MULTICHANNEL TMS COIL ARRAY
A method for controlling E-field intensity for a scalp region and a target brain region of a subject using a multichannel transcranial magnetic stimulation (TMS) coil array having a plurality of TMS coils and a plurality of coil elements includes calculating an electric field (E- field) for each coil element in the mTMS coil array and combining the E-field of two or more coil elements to create a predetermined E-field intensity for the scalp region and a predetermined E-field intensity for the target brain region. The method further includes determining an electrical signal for each coil element based on the calculated E-field corresponding to each coil element, applying the electrical signals determined for the two or more coil elements with combined E-fields simultaneously to the two or more coil elements, and applying the electrical signals determined for each coil element without combined E-fields to the corresponding coil element.
A61B 5/05 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
A61B 5/245 - Detecting biomagnetic fields, e.g. magnetic fields produced by bioelectric currents specially adapted for magnetoencephalographic [MEG] signals
A61B 5/291 - Bioelectric electrodes therefor specially adapted for particular uses for electroencephalography [EEG]
A61B 5/31 - Input circuits therefor specially adapted for particular uses for electroencephalography [EEG]
The present invention provides methods and compositions for reducing internalization and/or trafficking of tan in neuronal cells comprising contacting the cells with an effective amount of VLDL receptor antagonist. The invention further provides a method of treating or preventing Alzheimer's disease in a subject in need thereof, comprising administering to the subject an effective amount of a VLDL receptor antagonist.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
41.
GENETICALLY ENCODED SYSTEMS FOR GENERATING OXYGEN IN LIVING EUKARYOTIC CELLS
Described herein are compositions and methods for generating oxygen in living eukaryotic cells, e.g., animal cells, by expressing a Cld enzyme (i.e., chlorite dismutase, chlorite O2-lyase, chlorite:O2 lyase), optionally in combination with a transporter, in the cells.
Methods for single-cell sequencing of mitochondrial RNA are described. In some embodiments, the methods further involve the identification of malignant cells and/or characterization of tumor subclones in a biological sample.
Provided herein is a generative model based on transformer and diffusion models that learns a multi-modal representation of cells and tissues and reconstructs morphological information from transcriptome profiles to generate cellular and tissue images from single-cell expression profiles during inference.
Disclosed herein are apparatus and systems of optical devices and methods of using the same. The optical device may include: a first off-axis parabolic mirror and a second off-axis parabolic mirror, configured such that the first off-axis parabolic mirror and the second off-axis parabolic mirror are optically coupled and share a mechanical axis, wherein the second off-axis parabolic mirror is configured on a rotating platform; an excitation optical waveguide configured to deliver light from an excitation source to illuminate a sample using the first off-axis parabolic mirror and the second off-axis parabolic mirror; and an emission detector configured to receive light from the sample.
A61B 1/04 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor combined with photographic or television appliances
A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor
A61B 1/07 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor with illuminating arrangements using light-conductive means, e.g. optical fibres
G02B 17/06 - Catoptric systems, e.g. image erecting and reversing system using mirrors only
A61B 1/05 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor combined with photographic or television appliances characterised by the image sensor, e.g. camera, being in the distal end portion
A61B 1/273 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor for the upper alimentary canal, e.g. oesophagoscopes, gastroscopes
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
45.
METHODS AND SYSTEMS FOR PREDICTING DRUG RESPONSES AND COMBINATIONS
Provided herein are methods of using a machine learning model, e.g., optimal transport, in analyzing responses of biological samples to drugs and drug combinations, as determined by infrared and/or Raman microscopy.
G06N 20/10 - Machine learning using kernel methods, e.g. support vector machines [SVM]
G16H 20/00 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
G16H 50/00 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
46.
METHODS AND SYSTEMS FOR MASSIVELY SCALABLE DRUG DISCOVERY THROUGH CHEMICAL IMAGING AND MACHINE LEARNING
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
Inventor
Shu, Jian
Min, Wei
Abstract
Provided herein are methods of using a machine learning model to analyze a combination of imaging data and sequencing data to characterize cellular phenotypes and evaluate perturbation effects of drugs and genetic perturbation effects.
Disclosed herein are methods and devices for use in early detection of Richter's Syndrome. The methods include sequencing a panel of regions in cell-free DNA molecules and detecting one or more markers that are indicative of Richter's Syndrome.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
G16B 20/20 - Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
49.
INTERFERON FOR THE TREATMENT OF BRACHYURY-ASSOCIATED CANCERS AND NEOPLASMS
Provided herein are methods for treating a brachyury-associated cancer or neoplasm, e.g., chordoma, with a type I interferon in a subject in need thereof. The methods further include treating the brachyury-associated cancer or neoplasm with interferon alpha or interferon beta by injection of interferon protein into a subject in need thereof, wherein the interferon can be an interferon polypeptide or an interferon nucleic acid formulated for expression.
Provided herein are natural killer (NK) cells with increased, modified or deleted extracellular matrix (ECM) receptors, and methods of making and using the same for cancer immunotherapy, and treatment of chronic infections, inflammation, autoimmune diseases, or transplant rejection.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
A system and method for flow sorting includes a sample loader that is configured to receive a sample that contains one or more laser microparticles, wherein each laser microparticle is configured to generate laser emission with one or more distinct spectral peaks when excited. The system further includes a spectrometer receiving the laser emission from the one or more laser microparticle and generating spectral data and a processor configured to receive the spectral data and generate a sorting signal. The system also includes a switch configured to receive the sorting signal and route the one or more microparticles to a particular one of multiple collection channels based on the sorting signal.
G01N 15/1492 - Optical investigation techniques, e.g. flow cytometry specially adapted for sorting particles, e.g. by their size or optical properties within droplets
A method for acquiring a magnetic resonance image dataset of a field-of-view using a gradient-echo imaging protocol includes acquiring additional k-space lines within a central region of k-space at intervals throughout the imaging protocol, wherein the additional k-space lines are used for estimating motion parameters of the field-of-view. The imaging protocol has been amended by inserting additional gradient blips after at least some of the RF excitations, such that at least one additional gradient echo is generated, allowing the acquisition of at least one additional k-space line during one echo time.
G01R 33/561 - Image enhancement or correction, e.g. subtraction or averaging techniques by reduction of the scanning time, i.e. fast acquiring systems, e.g. using echo-planar pulse sequences
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
G01R 33/56 - Image enhancement or correction, e.g. subtraction or averaging techniques
G01R 33/565 - Correction of image distortions, e.g. due to magnetic field inhomogeneities
53.
SYSTEM AND METHOD FOR CLINICAL DISORDER ASSESSMENT
A system and method for clinical disorder assessment are disclosed. The method and the medical assessment system using the method include: obtaining sensor data indicative of movement of a user; generating a movement dataset by reducing dimensions of the sensor data; generating a plurality of submovement datasets based on the movement dataset; extracting a movement feature from a first subset of the plurality of submovement datasets; analyzing the movement feature from the first subset of the plurality of submovement datasets to a reference to determine a potential clinical disorder of the user; and generating a report that includes an indication and severity of the potential clinical disorder of the user. Other aspects, embodiments, and features are also claimed and described.
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
G16H 15/00 - ICT specially adapted for medical reports, e.g. generation or transmission thereof
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
54.
GENE FUSIONS ASSOCIATED WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS)
Provided herein are methods for diagnosing ALS, or determining risk of developing ALS. The methods include detection of a fusion as described herein. The methods can include detecting genomic fusions, fused transcripts, or fusion proteins (where proteins are produced) as described herein.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
Techniques for estimating a risk that a condition of a patient with a multiple myeloma (MM) precursor disease such as MGUS or SMM will progress into MM.
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
The present disclosure provides photocleavable rhodamine probes that facilitate live- and fixed-cell immunofluorescence. The ultra-fast spirocyclization of the dye following cleavage depletes the fluorescence signal, enabling cyclic multiplexed imaging.
G01N 15/01 - Investigating characteristics of particlesInvestigating permeability, pore-volume or surface-area of porous materials specially adapted for biological cells, e.g. blood cells
Methods of detecting and measuring positron emission for tumor margin assessment are described. The preferential uptake of radiotracers by certain tumor types provides a measurable parameter for distinguishing between healthy and cancerous tissue to enhance tumor margin determination. The methods provide more accurate margin delineation and reduced tissue resection size relative to conventional breast conserving surgery techniques.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
58.
COMPOSITIONS AND METHODS FOR IMPROVING MITOCHONDRIAL FUNCTION
A system for evaluating a subject, including: a processor in communication with a carbon monoxide (CO) detector, and a memory in communication with the processor having stored thereon a set of instructions which, when executed by the processor, cause the processor to: receive, from the CO detector, a measure of CO in a subject suspected of having at least one of autism spectrum disorder (ASD), autoimmunity, or inflammation; obtain a level of at least one biomarker associated with the subject based on receiving the measure of CO in the subject; and generate a report based on obtaining the level of the at least one biomarker.
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
G16H 15/00 - ICT specially adapted for medical reports, e.g. generation or transmission thereof
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
Described herein are systems and methods for improving the performance of and compliance with wearable garments. In some embodiments, a system comprises one or more sensors integrated within a wearable garment. The sensors are configured to generate data responsive to pressure exerted by the wearable garment on a user; and one or more processors coupled to the one or more sensors. The processors are configured to process the generated data to determine a duration of use of the wearable garment by the user; and in response to determining that the duration of use is less than a predetermined duration of use threshold, generating one or more notifications.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
62.
METHODS AND COMPOSITIONS FOR PROGNOSIS AND TREATMENT OF CANCER THERAPY-RELATED CARDIAC DYSFUNCTION
THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (USA)
Inventor
Aragam, Krishna
Huffman, Jennifer
Abstract
(0199] Provided herein are methods and compositions for the diagnosis, prognosis, and treatment of cancer therapy-related cardiac dysfunction (CTRCD). In particular, provided are methods and compositions for detecting a loss-of-function mutation in the CD36 gene. Provided are methods of determining the likelihood that a subject will respond to a treatment for CTRCD, based on the identification of a CD36 mutation in a sample from the subject.
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
Provided herein are methods for treating cancer and for selecting a cancer treatment based on the expression of Stag2/3 proteins and/or the presence of mutations in the genes encoding Stag2/3 proteins.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
64.
DYNAMIC LOW-ORDER SHIMMING FOR ARTERIAL SPIN LABELING
Systems and methods include executing a labeling phase of a pulse sequence while respective first shim currents are applied to first-order shim coils, respective second shim currents are applied to second-order shim coils, and a center frequency of an RF system is set to a first center frequency, switching, during a post-labeling delay of the pulse sequence, the first shim currents to third shim currents and the center frequency of the RF system to a second center frequency, executing a readout phase of the pulse sequence to acquire first MR data from an imaging volume of a subject while the respective third shim currents are applied, the respective second shim currents are applied s, and the center frequency is set to the second center frequency, and generating an image based on the first MR data.
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
G01R 33/54 - Signal processing systems, e.g. using pulse sequences
G01R 33/563 - Image enhancement or correction, e.g. subtraction or averaging techniques of moving material, e.g. flow-contrast angiography
A system and method are provided that include a portable neonatal magnetic resonance imaging (MRI) system. The system includes a static (B0) magnet comprising a plurality of magnetic elements arranged in a bulb array, a gradient coil, a patient bed movable relative to the B0 magnet and one or more gradient coils, and an imaging radiofrequency coil. A method for manufacturing is provided in which the arrangement of magnetic elements is optimized to produce a target magnetic field within a target scanning volume.
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
G01R 33/383 - Systems for generation, homogenisation or stabilisation of the main or gradient magnetic field using permanent magnets
G01R 33/563 - Image enhancement or correction, e.g. subtraction or averaging techniques of moving material, e.g. flow-contrast angiography
An image may be reconstructed from sensor data, which may include optical imaging data such as diffusion optical tomography (“DOT”) data. The sensor data are received by a computer system. A machine learning model is accessed with the computer system, where the machine learning model includes a first subnetwork that receives sensor data as an input and generates an intermediate image as a first output, and a second subnetwork that receives the first output from the first subnetwork and generates an enhanced image as a second output. The sensor data are input to the machine learning model using the computer system, generating an enhanced image as an output. The enhanced image may have higher spatial resolution, reduced noise, or other improved image quality. Structural images may be passed as an additional input to the second subnetwork of the machine learning model to increase the spatial resolution of the enhanced image.
The present invention provides a novel method to determine the likelihood of effectiveness of a treatment in an individual affected with or at risk for developing cancer. The method involves detecting the presence or absence of Met amplification in an individual. The presence of Met amplification indicates that a Met targeting treatment is likely to be effective. Preferably, the Met targeting treatment is PHA-665752 or PF-02341066. In addition, the present methods allow for the detection of cancer in an individual, wherein the presence of Met amplification indicates that cancer is present and further that it will be treatable, namely with a Met targeting treatment.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
A system and method is provided for improving the patient outcome for a subject having an aneurysm. The method includes determining that the subject has the aneurysm, positioning a vagus nerve stimulation system on the subject, the vagus nerve stimulation system being configured to provide an electrical stimulation to the vagus nerve of the subject. Stimulating the vagus nerve of the subject with the vagus nerve stimulation system to at least one of: prevent further growth of the aneurysm; decrease the likelihood that the aneurysm ruptures; and decrease effects of rupture, when the aneurysm of the subject ruptures.
The present disclosure provides methods of training a deep learning (DL)-based classifier to classify a digital histopathology image with respect to a phenotype, methods of classifying a digital histopathology image with respect to a phenotype, and methods of identifying a biological mediator associated with a pathology, pathophysiology, or other clinical characteristic. The disclosure further provides systems for implementation of these methods.
G06T 7/33 - Determination of transform parameters for the alignment of images, i.e. image registration using feature-based methods
G06V 10/25 - Determination of region of interest [ROI] or a volume of interest [VOI]
G06V 10/26 - Segmentation of patterns in the image fieldCutting or merging of image elements to establish the pattern region, e.g. clustering-based techniquesDetection of occlusion
G06V 10/77 - Processing image or video features in feature spacesArrangements for image or video recognition or understanding using pattern recognition or machine learning using data integration or data reduction, e.g. principal component analysis [PCA] or independent component analysis [ICA] or self-organising maps [SOM]Blind source separation
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
Provided herein are compositions and methods for delivering a molecular therapeutic to the ependyma of a subject. The methods comprise administering an adeno-associated virus (AAV) to the subject. The AAVs encode a therapeutic transgene under the control of an ependyma-specific promoter.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
71.
SYSTEM AND METHOD FOR HYBRID MAGNET DESIGN FOR MAGNETIC RESONANCE IMAGING SYSTEMS
Systems and methods are provided for a hybrid superconducting-permanent magnet MRI system. Permanent magnet elements may be used to supplement or shape the magnetic field produced by the superconducting windings. The hybrid design may increase field homogeneity or reduce the required bore length, thereby reducing the total system cost.
G01R 33/34 - Constructional details, e.g. resonators
G01R 33/00 - Arrangements or instruments for measuring magnetic variables
G01R 33/3815 - Systems for generation, homogenisation or stabilisation of the main or gradient magnetic field using electromagnets with superconducting coils, e.g. power supply therefor
G01R 33/383 - Systems for generation, homogenisation or stabilisation of the main or gradient magnetic field using permanent magnets
G01R 33/385 - Systems for generation, homogenisation or stabilisation of the main or gradient magnetic field using gradient magnetic field coils
72.
SYSTEMS AND METHODS FOR PORTABLE ULTRASOUND GUIDED CANNULATION
Systems and methods are provided for semi-automated, portable, ultrasound guided cannulation. The systems and methods provide for image analysis to provide for segmentation of vessels of interest from image data. The image analysis provides for guidance for insertion of a cannulation system into a subject which may be accomplished by a non-expert based upon the guidance provided. The guidance may include an indicator or a mechanical guide to guide a user for inserting the vascular cannulation system into a subject to penetrate the vessel of interest.
The present invention relates to methods for non-invasive detection of transplantation complications (e.g., rejection, infection, vascular failure, inflammation) or the risk thereof after tissue/organ/cell transplantation. The present methods allow for early, effective, and continuous monitoring of transplant health in a pigment-agnostic manner.
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A61P 5/50 - Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
75.
METHODS AND MATERIALS TO DISTINGUISH BETWEEN ACTIVE EOSINOPHILIC ESOPHAGITIS (EOE), EOE IN REMISSION, AND NON-EOE STATES
The invention provides methods for diagnosing eosinophilic esophagitis (EoE) in a subject and methods for determining an EoE state (active or remission) in a subject. The methods include detecting elevated expression levels of GPR15 protein or a fragment thereof and/or CD38 protein or a fragment thereof in a biological sample from the subject. Panels, compositions, and kits are also provided.
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (Canada)
THE GENERAL HOSPITAL CORPORATION D/B/A MASSACHUSETTS GENERAL HOSPITAL (USA)
Inventor
Keshavjee, Shafique
Kleinstiver, Benjamin Peter
Davidson, Alan Richard
Cypel, Marcelo
Mesaki, Kumi
Abstract
Provided herein are non-naturally occurring CRISPR/Cas system for modifying a genome at a cold temperature, comprising a cold-tolerant Cas effector or functional fragment thereof and a guide RNA. Also provided are methods of modifying a genome of a cell at a cold temperature.
An imaging and biopsy device, including: a tethered capsule that is configured to be swallowed; a first optical fiber transmitting an electromagnetic radiation that at least partially impacts an anatomical structure; and a biopsy apparatus configured to collect tissue from the anatomical structure, the electromagnetic radiation at least partially or temporarily impacting the biopsy apparatus, and at least a portion of the first optical fiber and the biopsy apparatus being associated with the tethered capsule.
A61B 1/07 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor with illuminating arrangements using light-conductive means, e.g. optical fibres
A61B 1/04 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor combined with photographic or television appliances
A61B 1/05 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor combined with photographic or television appliances characterised by the image sensor, e.g. camera, being in the distal end portion
A61B 10/04 - Endoscopic instruments, e.g. catheter-type instruments
G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
78.
METHOD AND DEVICE TO PREDICT EXERCISE PEAK VO2, CARDIOVASCULAR OUTCOMES AND FUTURE DEATH USING ECG DEEP LEARNING MODELS
A computer-implemented method to determine peak oxygen consumption ({dot over (V)}O2 PEAK) from electrocardiogram (ECG) waveform data includes the steps of recording, by at least one first computing device, an electrocardiogram (ECG) waveform data of a subject; transmitting, by the at least one first computing device, the ECG waveform data, to at least one second computing device communicatively coupled to the at least one first computing device; determining, by the at least one second computing device, a {dot over (V)}O2 PEAK of the subject using a convolutional neural network; and transferring, by the at least one second computing device, the {dot over (V)}O2 PEAK to the first computing device associated or a device associated with the subject.
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/349 - Detecting specific parameters of the electrocardiograph cycle
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
79.
MINOR HISTOCOMPATIBILITY ANTIGEN MARKERS ASSOCIATED WITH GRAFT VERSUS LEUKEMIA EFFECT AND USES THEREOF
Minor histocompatibility antigens (mHAgs) associated with graft versus leukemia (GvL) clinical outcomes identified by single nucleotide polymorphisms (SNPS) and uses thereof are described.
C12Q 1/6827 - Hybridisation assays for detection of mutation or polymorphism
A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
C12Q 1/6881 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
C40B 20/00 - Methods specially adapted for identifying library members
C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
C12Q 1/6837 - Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
Minor histocompatibility antigens (mHAgs) associated with graft versus host disease (GvHD) clinical outcomes identified by single nucleotide polymorphisms (SNPS) and uses thereof are described. Further, mHAgs cross-reactive against gut-tropic viral epitopes associated with acute GvHD of the gut and uses thereof are described.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C12N 15/62 - DNA sequences coding for fusion proteins
82.
MATERIALS AND METHODS FOR LUMINESCENCE-BASED CARBON DIOXIDE SENSING
A device for carbon dioxide monitoring is disclosed. The device comprises: a photoluminescent carbon dioxide-sensitive probe comprising a polymer matrix and a sensing dye; a photon source configured to direct photons at the probe; a photodetector configured to detect light emitted from the probe when the photon source directs photons at the probe; a carbon dioxide permeable light redirection layer, wherein the carbon dioxide-sensitive probe is positioned between the light redirection layer and the photodetector; and a controller in electrical communication with the photon source and the photodetector, the controller being configured to execute a program stored in the controller to calculate a level of carbon dioxide adjacent the probe from an electrical signal received from the photodetector. In one form, the polymer matrix comprises a polymer selected from the group consisting of acrylate polymers, methacrylate polymers, polyurethane polymers, and blends and copolymers thereof.
Systems and methods are provided that permanently modify an airway, such as a nasal airway without surgical intervention. The system to modify an airway can include one or more nasal inserts having different geometries or capable of being configured into different geometries to incrementally adjust bone or cartilage in the nasal airway over an extended period of time.
As described below, the present invention features compositions, panels of biomarkers, and methods for selecting a subject with chronic lymphocytic leukemia (CLL) for treatment using an agent and/or for inclusion in a clinical trial using the agent to treat CLL.
A61K 31/635 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide having a heterocyclic ring, e.g. sulfadiazine
A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61K 31/4162 - 1,2-Diazoles condensed with heterocyclic ring systems
A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/5025 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
Provided herein are CRISPR guide RNAs (gRNAs), which includes chimeric Cas9 single guide RNAs (sgRNAs) and CRISPR RNAs (crRNAs), comprising a U6 and/or U6cap motif. The crRNAs include CasPhi crRNAs, and Cas12a crRNAs (including AsCas12a and LbCas12a crRNAs) comprising a U6 and/or U6cap motif, e.g., at the 5' end of the RNA, and the gRNAs include SpCas9-, Cas12a-, or CasPhi-gRNAs including SpCas9-, Cas12a-, or CasPhi-based prime editor pegRNAs comprising a U6 and/or U6cap motif, e.g., at the 3' end of the pegRNA. Also provided are compositions comprising the crRNAs and gRNAs, e.g., pegRNAs, and their corresponding proteins, as well as methods of using the same for editing of DNA.
G06V 10/26 - Segmentation of patterns in the image fieldCutting or merging of image elements to establish the pattern region, e.g. clustering-based techniquesDetection of occlusion
Error correction of nucleic acid sequencing reads is described. A machine learning model may be trained using aligned sequencing reads generated during a nucleic acid sequencing event, the aligned sequencing reads aligned to a reference sequence. The trained machine learning model may output predicted reference sequences for the aligned sequencing reads that have a position of mismatch with the reference sequence. The aligned sequencing reads may be selectively corrected according to whether the machine learning model predicts that the aligned sequencing reads are variants or sequencing errors based on the predicted reference sequences relative to the reference sequence.
Apparatus and method can be provided for obtaining at least one anatomical sample. For example, it is possible to provide and insert a housing into a body or provided on a hydrated anatomical structure. Further, with a source, it is possible to emit an electromagnetic radiation which causes at least the anatomical sample(s) to attach to at least one portion of the housing. A compound can be provided on a surface of the housing, and the source provides the radiation to the compound and changes properties thereof to be adhesive. The source can provide the radiation to the housing, and can change properties of a surface thereof to be adhesive. A component can be provided on a surface of the anatomical structure, and the source provides the radiation to the compound and changes properties thereof to be adhesive.
A61B 10/04 - Endoscopic instruments, e.g. catheter-type instruments
A61B 1/04 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor combined with photographic or television appliances
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 10/02 - Instruments for taking cell samples or for biopsy
The disclosure is directed to methods and compositions for treating cancers characterized by cells comprising chimeric antigen receptors (CARs) that bind CD70 and T-cell engaging antibody molecules (TEAMs) that bind CD33, nucleic acid molecules encoding chimeric antigen receptors (CARs) that bind CD70 and/or TEAMs that bind CD33, and compositions and methods related thereto.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61K 39/00 - Medicinal preparations containing antigens or antibodies
91.
COMPOSITION FOR TREATING GOUT CONTAINING CYCLODEXTRIN-CONJUGATED POLYMER NANO-DRUG AND METHOD FOR TREATING GOUT
THE INDUSTRY & ACADEMIC COOPERATION IN CHUNGNAM NATIONAL UNIVERSITY (IAC) (Republic of Korea)
THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
Kang, Min Woong
Kim, Jin Hyun
Choi, Hak Soo
Abstract
The present invention can provide a composition for treating gout or a method for treating gout, the composition containing a nano-drug in which a cyclodextrin moiety is conjugated to an amino group of a polymer, wherein a visible or near-infrared fluorophore is further conjugated to a carboxyl group of the polymer or the nano-drug further contains at least one gout therapeutic agent, which forms a complex together with the cyclodextrin moiety.
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
A61K 31/5415 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (Republic of Korea)
THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
Kim, Hyun Koo
Rho, Ji-Yun
Jeon, Ok Hwa
Kim, Kyungsu
Choi, Byeong Hyeon
Choi, Hak Soo
Bao, Kai
Abstract
The present invention relates to a composition for cancer diagnosis targeting a tumor and/or a tumor microenvironment and use thereof and, more specifically, provides a fluorescent contrast agent composition targeting biomolecules overexpressed in cancer cells and a tumor microenvironment. According to the present invention, a fluorescent contrast agent capable of targeting both cancer (folate receptor alpha-expressing cancer) cells and tumor-related macrophages in a tumor microenvironment can be provided.
C07D 209/18 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
The disclosure relates to methods and kits for detecting tau, e.g., tau that is phosphorylated at amino acid position T181 (pTau181), tau that is phosphorylated at amino acid position T217 (pTau217), and/or total tau. The disclosure further provides methods for distinguishing between individuals whose cognitive condition will remain stable and whose cognitive condition will decline during their lifetime. The disclosure also provides methods for determining the eligibility of individuals for participation in clinical trials for Alzheimer's disease treatments. Also provided are methods for distinguishing between individuals with Alzheimer's disease and non-Alzheimer's dementia, and for monitoring response to treatment for Alzheimer's disease.
The invention provides agonistic TNFR2 antibodies and antigen-binding fragments thereof and encompasses the use of these antibodies as therapeutics to promote the proliferation of regulatory T cells (T-reg) for the treatment of immunological diseases. Antibodies of the invention can be used to potentiate the T-reg-mediated deactivation of self- and allergen-reactive T- and B-lymphocytes, and can thus be used to treat a wide variety of indications, including autoimmune diseases, allergic reactions, asthma, graft-versus-host disease, and allograft rejection, among others.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Described in several example embodiments herein are engineered bifunctional receptors that can include an E3 ligase binding domain and a target binding domain operatively coupled to the E3 ligase binding domain. In some embodiments, the engineered bifunctional receptors are capable of targeted degradation of a target protein. Also described in several example embodiments herein are compositions, formulations, and cells that can include or generate the engineered bifunctional receptors and uses thereof.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
One of the side-effects of decompensation in heart failure is excessive accumulation of interstitial fluid. Systems and methods are provided for measuring the edema using near infrared (NIR) light, in the tissue at the periphery of a patient with heart failure. This edema value, calculated from the water fraction in the tissue at the periphery, is used to determine if the patient is at risk of decompensation. If the patients is at risk of decompensation, the system includes a user interface such as a display, a speaker, or a haptic feedback device, to alert the patient to seek medical intervention.
A61B 5/0295 - Measuring blood flow using plethysmography, i.e. measuring the variations in the volume of a body part as modified by the circulation of blood therethrough, e.g. impedance plethysmography
A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using optical sensors, e.g. spectral photometrical oximeters
G01N 21/359 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light using near infrared light
97.
TUNABLE SHEAR WAVE FRONT GENERATION FOR BIOMECHANICAL MEASUREMENT OF BIOLOGICAL TISSUE
Some aspects of the described technology may include a method, including inducing a wave field in a biological sample, the wave field comprising waves having a wave frequency, scanning the sample at a scanning velocity to perform a plurality of spatial measurements of the sample, determining spatial data from the plurality of spatial measurements, amplitude demodulating the spatial data based on the wave frequency and the scanning velocity, and generating displacement data for the biological sample based on the amplitude demodulated spatial data.
The Industry & Academic Cooperation in Chungnam National University (IAC) (Republic of Korea)
The General Hospital Corporation (USA)
Inventor
Kang, Min Woong
Kim, Jin Hyun
Choi, Hak Soo
Abstract
The present invention can provide a composition for treating gout or a method for treating gout, the composition containing a nano-drug in which a cyclodextrin moiety is conjugated to an amino group of a polymer, wherein a visible or near-infrared fluorophore is further conjugated to a carboxyl group of the polymer or the nano-drug further contains at least one gout therapeutic agent, which forms a complex together with the cyclodextrin moiety.
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 47/59 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
A61P 19/06 - Antigout agents, e.g. antihyperuricemic or uricosuric agents
99.
DUAL MODALITY INTRAVASCULAR CATHETER SYSTEM COMBINING PULSE-SAMPLING FLUORESCENCE LIFETIME IMAGING AND POLARIZATION-SENSITIVE OPTICAL COHERENCE TOMOGRAPHY
A dual modality catheter-based imaging system that is capable of simultaneously acquiring FLIm and PSOCT data is described. The system can acquire co-registered FLIm and PSOCT data in co-registration and birefringent phantoms and coronary artery specimens, and is compatible with a clinical setting, where it enables a comprehensive image-based assessment of plaque pathophysiology, leading to understanding of mechanisms underlying plaque formation and supporting the development of new therapies.
G02B 6/42 - Coupling light guides with opto-electronic elements
H04B 10/25 - Arrangements specific to fibre transmission
G02B 23/26 - Instruments for viewing the inside of hollow bodies, e.g. fibrescopes using light guides
A61B 1/07 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor with illuminating arrangements using light-conductive means, e.g. optical fibres
100.
WIRELESS INGESTIBLE LUMINAL DIAGNOSTIC CAPSULE THAT AUTONOMOUSLY TREATS A CONDITION
An apparatus for detecting and treating gastrointestinal pathology. The apparatus includes a wireless capsule, where the wireless capsule includes at least one of: an optical imaging system, a thermal imaging system, or a camera. The camera is a narrow band imaging system, a white light imaging system, or both.
A61B 1/04 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor combined with photographic or television appliances
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
